Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01236417
First received: November 5, 2010
Last updated: April 12, 2012
Last verified: April 2012
  Purpose

This is a pilot study of a specifically designed exercise intervention developed for breast cancer patients with aromatase-inhibitor related joint pain.


Condition Intervention
Breast Cancer
Arthralgia
Behavioral: Exercising block

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia

Resource links provided by NLM:


Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • Effects of exercise [ Time Frame: Length of study ] [ Designated as safety issue: No ]
    To assess the effect of an exercise intervention in breast cancer patients with arthralgia secondary to adjuvant treatment with aromatase inhibitors.


Secondary Outcome Measures:
  • Feasibility of Multi-institutional study [ Time Frame: Length of the study ] [ Designated as safety issue: No ]
    To perform a pilot to access the feasibility of a multi-institutional approach


Enrollment: 27
Study Start Date: March 2010
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Exercise
Subjects will be participating in a home-based flexibility and exercise program
Behavioral: Exercising block
Exercising for 8 weeks using an elastic band

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post menopausal women with a history of estrogen positive breast cancer who are receiving aromatase inhibitors for at least one month.
  • Patients must complain of mild to moderate arthralgia.
  • Ability to understand and sign informed consent.
  • Patients meet criteria for low to moderate risk for moderate exercise based oon the ACSM guidelines.

Exclusion Criteria:

  • Inability to comply with study requirements.
  • Metastatic breast cancer.
  • Patients with orthopedic or neuromuscular disorders that preclude participation in exercise.
  • Rheumatoid arthritis.
  • History of MI, angina or congestive heart failure.
  • Pregnant or lactating females.
  • Patients that are high risk for moderate exercise based on ACSM risk classification.
  • Patients who exceed minimal physical activity recommendations from the US Surgeon General's Report: Accumulation of 30 minutes or more of moderate physical activity on most days of the week.
  • Morbidly obese with BMI ≥ 40
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01236417

Locations
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Roswell Park Cancer Institute
Investigators
Principal Investigator: Tracy O'Connor, MD Roswell Park Cancer Institute
  More Information

No publications provided

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT01236417     History of Changes
Other Study ID Numbers: I 169310
Study First Received: November 5, 2010
Last Updated: April 12, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Arthralgia
Breast Neoplasms
Breast Diseases
Joint Diseases
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Pain
Signs and Symptoms
Skin Diseases

ClinicalTrials.gov processed this record on October 30, 2014